WATERTOWN, Mass.--(BUSINESS WIRE)--
pSivida Corp. (NASDAQ:PSDV)
(ASX:PVA), a leader in developing sustained release, drug delivery
products for treatment of back-of-the-eye diseases, announced today that
it has entered into a securities purchase agreement with institutional
investors to raise gross proceeds of approximately $5.36 million in a
registered direct offering through the sale of a total of 2,494,419
shares of the Company's common stock and warrants to purchase 623,605
shares of its common stock.
The common stock and warrants will be sold in units, with each unit
consisting of one share of common stock and the equivalent of a warrant
to purchase 0.25 shares of common stock. Each purchaser will receive
warrants to purchase a number of whole shares of common stock equal to
25% of the number of shares of common stock purchased by such purchaser.
Each unit will be sold at a negotiated price of $2.15 per unit. Each
warrant will be exercisable for one share of common stock, has an
exercise price of $2.50 per share and will be exercisable during the
period commencing six months after the date of its original issuance and
ending five years from date of its issuance. These securities are being
offered through an effective registration statement.
The offering is expected to close on or about August 7, 2012 subject to
the satisfaction of customary closing conditions. The Company intends to
use the proceeds from this offering for general corporate purposes,
which may include funding its clinical trials for posterior uveitis and
other business operations.
Rodman & Renshaw, LLC acted as sole placement agent for the offering.
A shelf registration statement relating to the shares of common stock
and warrants to purchase common stock issued in the offering has been
filed with the Securities and Exchange Commission (SEC) and has been
declared effective. A prospectus supplement relating to the offering
will be filed with the SEC. Copies of the prospectus supplement and
accompanying prospectus may be obtained from Rodman & Renshaw, LLC by
calling 212-201-8064 or by email at placements@rodm.com.
This announcement is neither an offer to sell nor a solicitation of an
offer to buy any of our shares of common stock. No offer, solicitation
or sale will be made in any jurisdiction in which such offer,
solicitation or sale is unlawful.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a
controlled and steady rate for months or years. pSivida is currently
focused on treatment of chronic diseases of the back of the eye
utilizing its core technology systems, Durasert™ and BioSilicon™. The
injectible, sustained release micro-insert ILUVIEN® for the treatment of
chronic Diabetic Macular Edema (DME), licensed to Alimera Sciences,
Inc., has received marketing authorization in Austria, France, Germany,
Portugal and the U.K. and is awaiting authorization in Italy and Spain.
The United States Food and Drug Administration (FDA) has cleared
pSivida's Investigational New Drug application (IND) to treat posterior
uveitis with the same micro-insert. An investigator-sponsored clinical
trial is ongoing for an injectable, bioerodible insert to treat glaucoma
and ocular hypertension. pSivida's two FDA-approved products, Retisert®
and Vitrasert®, are implants that provide long-term, sustained drug
delivery to treat two other chronic diseases of the retina.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties and
potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or believe may
occur in the future are forward-looking statements. The following are
some of the factors that could cause actual results to differ materially
from the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements: no assurance
that Alimera will resubmit its application or be able to demonstrate to
the FDA that the benefits outweigh the risks of ILUVIEN for DME using
data from their two previously completed pivotal Phase III clinical
trials (FAME® Study), that additional clinical trials will not be
required, that the population of chronic DME patients will be acceptable
to the FDA or that Alimera will be able to obtain regulatory approval
for ILUVIEN for DME in the U.S.; ability of Alimera to consummate its
pending financing; the timing and conditions for additional regulatory
approvals are subject to decisions by regulators; necessity to raise
additional capital to finance Phase III uveitis trials as well as other
working capital needs; ability to obtain additional capital; ability to
initiate and complete clinical trials and obtain regulatory approval of
product candidates; adverse side effects; Alimera's ability to
successfully obtain regulatory approval of and commercialize ILUVIEN for
DME in the EU; actions with respect to regulatory approval of ILUVIEN
for DME in the U.S.; ability to attain profitability; exercise by
Pfizer, Inc. of the Latanoprost Product option; further impairment of
intangible assets; fluctuations in operating results; decline in royalty
revenues; ability to find partners to develop and market products;
termination of license agreements; competition; market acceptance of
products and product candidates; reduction in use of products as a
result of future guidelines, recommendations or studies; ability to
protect intellectual property and avoid infringement of others'
intellectual property; retention of key personnel; product liability;
consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs
of international business operations; credit and financial market
conditions; legislative or regulatory changes; volatility of stock
price; possible dilution; possible influence by Pfizer; ability to pay
any registration penalties; absence of dividends; and other factors
described in our filings with the SEC. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. Our forward-looking statements speak only as
of the dates on which they are made. We do not undertake any obligation
to publicly update or revise our forward-looking statements even if
experience or future changes makes it clear that any projected results
expressed or implied in such statements will not be realized.
In US:
Martin E. Janis & Company, Inc.
Beverly Jedynak,
312-943-1123
President
bjedynak@janispr.com
or
In
Australia:
pSivida Corp.
Brian Leedman, +61 (0) 41 228 1780
Vice
President, Investor Relations
brianl@psivida.com
Source: pSivida Corp.
News Provided by Acquire Media
